Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autism Spectrum Disorder01:19

Autism Spectrum Disorder

1.8K
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
1.8K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Modeling in Therapy01:26

Modeling in Therapy

736
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
736
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.4K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.4K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.5K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sleep profiles in individuals with rare neurogenetic syndromes.

Developmental medicine and child neurology·2026
Same author

Research Review: Emotion regulation in individuals with intellectual disability - an integrative review.

Journal of child psychology and psychiatry, and allied disciplines·2026
Same author

Real-World Data From a Group Parent Management Training Program Enhanced Using Artificial Intelligence: Qualitative Study.

JMIR formative research·2026
Same author

Correction: Exploring Correlations of Unemployment, Underemployment, and Well-Being Among Autistic Job Seekers by Race in the United States.

Journal of autism and developmental disorders·2026
Same author

Child Quality of Life as an Outcome Following Pivotal Response Treatment: Findings From Four Randomized Controlled Trials With Autistic Children.

Journal of autism and developmental disorders·2026
Same author

Exploring Correlations of Unemployment, Underemployment, and Well-Being Among Autistic Job Seekers by Race in the United States.

Journal of autism and developmental disorders·2026
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Related Experiment Video

Updated: Apr 8, 2026

Dynamic Clamp Methods to Investigate Impaired Neuronal Excitability Associated with Autism
08:44

Dynamic Clamp Methods to Investigate Impaired Neuronal Excitability Associated with Autism

Published on: October 17, 2025

826

Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date.

Lawrence K Fung1, Antonio Y Hardan

  • 1Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA, 94305-5717, USA, lkfung@stanford.edu.

CNS Drugs
|June 25, 2015
PubMed
Summary
This summary is machine-generated.

New autism spectrum disorder (ASD) treatments focus on glutamatergic neurotransmission. Research explores medications targeting this system in animal models and human clinical trials for ASD.

More Related Videos

Video Imaging and Spatiotemporal Maps to Analyze Gastrointestinal Motility in Mice
07:41

Video Imaging and Spatiotemporal Maps to Analyze Gastrointestinal Motility in Mice

Published on: February 3, 2016

14.9K
Strategies for Assessing Autistic-Like Behaviors in Mice
07:38

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

2.8K

Related Experiment Videos

Last Updated: Apr 8, 2026

Dynamic Clamp Methods to Investigate Impaired Neuronal Excitability Associated with Autism
08:44

Dynamic Clamp Methods to Investigate Impaired Neuronal Excitability Associated with Autism

Published on: October 17, 2025

826
Video Imaging and Spatiotemporal Maps to Analyze Gastrointestinal Motility in Mice
07:41

Video Imaging and Spatiotemporal Maps to Analyze Gastrointestinal Motility in Mice

Published on: February 3, 2016

14.9K
Strategies for Assessing Autistic-Like Behaviors in Mice
07:38

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

2.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Autism Spectrum Disorder Research

Background:

  • Autism spectrum disorder (ASD) is increasingly linked to disruptions in glutamatergic neurotransmission.
  • Animal models show social deficits associated with glutamatergic system dysregulation.

Purpose of the Study:

  • To review evidence linking glutamatergic system dysfunction to ASD.
  • To summarize pre-clinical and clinical development of pharmacologic interventions targeting this system for ASD.

Main Methods:

  • Review of scientific literature on glutamatergic neurotransmission in ASD.
  • Analysis of pre-clinical studies in animal models.
  • Summary of ongoing and completed clinical trials of glutamatergic modulators in ASD.

Main Results:

  • Evidence supports glutamatergic system involvement in ASD pathobiology.
  • Several investigational medications targeting glutamatergic systems show promise.
  • Specific examples of pre-clinical and clinical agents are detailed.

Conclusions:

  • Understanding glutamatergic pathways offers new therapeutic avenues for ASD.
  • Further research is needed to overcome limitations and optimize treatments.
  • Future opportunities exist for developing targeted pharmacotherapies for ASD.